TCM Prescription: Nian Mo Kui Yang Powder



Prescription Description
Prescription IDTCMFx6809
Pinyin NameNian Mo Kui Yang San
Chinese Name粘膜溃疡散
English NameNian Mo Kui Yang Powder
Function Description喉痹, 口疮
IndicationsPharyngitis, Aphtha
Disease ICD-11 Category CA0Z [Upper respiratory tract disorders, unspecified, 上呼吸道疾患,未特指的 ];
DA01.10 [Oral aphthae or aphtha-like ulceration, 口腔阿弗他溃疡或阿弗他样溃疡 ];
Human Tissues Associated with IndicationLung, Liver, Spleen
ReferenceCFDA
Reference Book/linkhttp://samr.cfda.gov.cn/WS01/CL0001/
Prescription Components
Component ID Latin Name Chinese Name Component Quantity Barcode
TCMH1678 Indigo naturalis 青黛 TCMH1678
TCMH547 Catechu 儿茶 TCMH547
TCMH183 Dryobalanops aromatica 冰片 TCMH183 GBVK4926-11
Reference: CFDA

Targeted Human Proteins by the Ingredients of Prescription

Target ID Gene Symbol Target Name Target Class Uniprot ID
TCMT689 TGM2 Protein-glutamine gamma-glutamyltransferase Transferase P21980


Targeted Pathogenic Microbes by the Ingredients of Prescription

Target ID Target Name
TCMT1229 Enterococcus faecalis
TCMT1255 Human immunodeficiency virus 1
TCMT1353 Plasmodium yoelii
TCMT1438 Plasmodium falciparum
TCMT1439 Mycobacterium smegmatis
TCMT1455 Mycobacterium tuberculosis H37Rv
TCMT1463 Mycobacterium tuberculosis
TCMT1465 Entamoeba histolytica

Gene Ontology Associated to Targeted Human Proteins

GO Term GO Name Enriched Genes Log10 Adjusted P-value


KEGG Pathways Associated to Targeted Human Proteins

KEGG Pathway ID Enriched Genes Log10 Adjusted P-value


Target Exprsssion in Healthy Human Tissues (protein & mRNA level)

Protein expression data was from the "Human Proteome Map" dataset
mRNA expression data was from the "GTEx" dataset



Average Target Expression (Fold Change) in Multiple Disease Conditions

Fold Change with Corresponding Normal Samples
Click each cell within the heatmap to access gene expression of individual patient samples
Data Section
Select to Download
1. General Information of Prescription  
2. Putative Targets  
3. Activity & References for Filtering Putative Targets  
4. GO & Pathway